miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review

Thanh Hoa Vo, Esam EL-Sherbieny Abdelaal, Emmet Jordan, Orla O'Donovan, Edel A. McNeela, Jai Prakash Mehta, Sweta Rani

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Breast cancer is the most common type of lethal cancer in women globally. Women have a 1 in 8 chance of developing breast cancer in their lifetime. Among the four primary molecular subtypes (luminal A, luminal B, HER2+, and triple-negative), HER2+ accounts for 20–25 % of all breast cancer and is rather aggressive. Although the treatment outcome of HER2+ breast cancer patients has been significantly improved with anti-HER2 agents, primary and acquired drug resistance present substantial clinical issues, limiting the benefits of HER2-targeted treatment. MicroRNAs (miRNAs) play a central role in regulating acquired drug resistance. miRNA are single-stranded, non-coding RNAs of around 20–25 nucleotides, known for essential roles in regulating gene expression at the post-transcriptional level. Increasing evidence has demonstrated that miRNA-mediated alteration of gene expression is associated with tumorigenesis, metastasis, and tumor response to treatment. Comprehensive knowledge of miRNAs as potential markers of drug response can help provide valuable guidance for treatment prognosis and personalized medicine for breast cancer patients.

Original languageEnglish
Article number101588
Pages (from-to)101588
JournalBiochemistry and Biophysics Reports
Volume37
DOIs
Publication statusPublished - 01 Mar 2024

Keywords

  • Drug resistance
  • Drug sensitivity
  • HER2 target therapy
  • HER2-Positive breast cancer
  • miRNAs
  • Treatment response

Fingerprint

Dive into the research topics of 'miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review'. Together they form a unique fingerprint.

Cite this